Featured Research

from universities, journals, and other organizations

Double duty: Immune system regulator found to protect brain from effects of stroke

Date:
November 28, 2012
Source:
Johns Hopkins Medicine
Summary:
A small molecule known to regulate white blood cells has a surprising second role in protecting brain cells from the deleterious effects of stroke, researchers report. The molecule, microRNA-223, affects how cells respond to the temporary loss of blood supply brought on by stroke -- and thus the cells' likelihood of suffering permanent damage.

A small molecule known to regulate white blood cells has a surprising second role in protecting brain cells from the deleterious effects of stroke, Johns Hopkins researchers report. The molecule, microRNA-223, affects how cells respond to the temporary loss of blood supply brought on by stroke -- and thus the cells' likelihood of suffering permanent damage.

"We set out to find a small molecule with very specific effects in the brain, one that could be the target of a future stroke treatment," says Valina Dawson, Ph.D., a professor in the Johns Hopkins University School of Medicine's Institute for Cell Engineering. "What we found is this molecule involved in immune response, which also acts in complex ways on the brain. This opens up a suite of interesting questions about what microRNA-223 is doing and how, but it also presents a challenge to any therapeutic application." A report on the discovery is published in the Nov. 13 issue of the Proceedings of the National Academy of Sciences.

RNA is best known as a go-between that shuttles genetic information from DNA and then helps produce proteins based on that information. But, Dawson explains, a decade ago researchers unearthed a completely different class of RNA: small, nimble fragments that regulate protein production. In the case of microRNA, one member of this class, that control comes from the ability to bind to RNA messenger molecules carrying genetic information, and thus prevent them from delivering their messages. "Compared with most ways of shutting genes off, this one is very quick," Dawson notes.

Reasoning that this quick action, along with other properties, could make microRNAs a good target for therapy development, Dawson and her team searched for microRNAs that regulate brain cells' response to oxygen deprivation.

To do that, they looked for proteins that increased in number in cells subjected to stress, and then examined how production of these proteins was regulated. For many of them, microRNA-223 played a role, Dawson says.

In most cases, the proteins regulated by microRNA-223 turned out to be involved in detecting and responding to glutamate, a common chemical signal brain cells use to communicate with each other. A stroke or other injury can lead to a dangerous excess of glutamate in the brain, as can a range of diseases, including autism and Alzheimer's. Because microRNA-223 is involved in regulating so many different proteins, and because it affects glutamate receptors, which themselves are involved in many different processes, the molecule's reach turned out to be much broader than expected, says Maged M. Harraz, Ph.D., a research associate at Hopkins who led the study. "Before this experiment, we didn't appreciate that a single microRNA could regulate so many proteins," he explains.

This finding suggests that microRNA-223 is unlikely to become a therapeutic target in the near future unless researchers figure out how to avoid unwanted side effects, Dawson says.

Other authors on the paper are Stephen M. Eacker, Ph.D., Xueqing Wang, Ph.D., and Ted M. Dawson, M.D., Ph.D., from the Johns Hopkins University School of Medicine.

This work was supported by a grant from the National Institutes of Health (grant DA000266) and by a Maryland Stem Cell Research Fund fellowship.


Story Source:

The above story is based on materials provided by Johns Hopkins Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. W. Luo, R. Chang, J. Zhong, A. Pandey, G. L. Semenza. PNAS Plus: Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proceedings of the National Academy of Sciences, 2012; DOI: 10.1073/pnas.1217394109

Cite This Page:

Johns Hopkins Medicine. "Double duty: Immune system regulator found to protect brain from effects of stroke." ScienceDaily. ScienceDaily, 28 November 2012. <www.sciencedaily.com/releases/2012/11/121128143549.htm>.
Johns Hopkins Medicine. (2012, November 28). Double duty: Immune system regulator found to protect brain from effects of stroke. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/11/121128143549.htm
Johns Hopkins Medicine. "Double duty: Immune system regulator found to protect brain from effects of stroke." ScienceDaily. www.sciencedaily.com/releases/2012/11/121128143549.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins